Form 4: Centessa Pharmaceuticals Executive Exercises Options and Sells Shares
SEC Form 4 Filing
Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, exercised options and sold 10,000 shares of company stock on December 26, 2024.
Summary
- Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, exercised options to acquire 10,000 ordinary shares at a price of $3.85 per share on December 26, 2024.
- On the same day, Mr. Weinhoff sold 10,000 ordinary shares at a weighted average price of $17.0399 per share.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2024.
- Following these transactions, Mr. Weinhoff directly owns 183,266 ordinary shares.
- The share options were granted with a vesting schedule, with 1/48th of the shares vesting monthly starting March 1, 2023.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction by an executive, with no indication of positive or negative sentiment. It is a standard regulatory filing.
Industry Context
This is a routine filing related to executive stock transactions and is common in the pharmaceutical industry. It reflects the standard practice of executives exercising stock options and selling shares, often under pre-arranged trading plans.
Comparison to Industry Standards
- The use of Rule 10b5-1 trading plans is a common practice among executives in publicly traded companies, including those in the pharmaceutical sector, to avoid accusations of insider trading.
- The vesting schedule of the options is typical for executive compensation packages.
- The price range of the share sales is within the normal fluctuations of the stock price.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the sale of shares by an executive.
- The information is relevant to shareholders as it provides transparency into executive stock transactions.
Key Dates
| Date | Description |
|---|---|
| 03/01/2023 | First vesting date for the share options. |
| 05/22/2024 | Date the Rule 10b5-1 trading plan was adopted. |
| 12/26/2024 | Date of the option exercise and share sale. |
Keywords
Centessa Pharmaceuticals, insider trading, Form 4, share options, stock sale, Rule 10b5-1, Gregory M. Weinhoff, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.